Cleveland Clinic London has appointed Heather Shaw, MD, FRCP, as Oncology Vice Chief, reinforcing the organization’s commitment to expanding access to advanced, multidisciplinary cancer care in the United Kingdom.
Dr. Shaw will lead oncology strategy and service development across Cleveland Clinic London. She will work with clinical and operational leaders to expand oncology services, recruit leading specialists, advance research and innovation, and develop integrated models of care. The new oncology center at 40 Grosvenor Place in Belgravia will a comprehensive cancer program in the UK independent health-care market and is anticipated to open at the end of 2027.
Heather Shaw, MD, FRCP
An internationally recognized oncologist, Dr. Shaw is known for her expertise in melanoma therapies, immunotherapy, and developing novel cancer therapies. In addition to her role at Cleveland Clinic London, she is a consultant medical oncologist and leads the Medical Oncology Skin Cancer Service at University College London Hospital and is a consultant medical oncologist at Mount Vernon Cancer Centre, having recently stepped down as Deputy Medical Director to take up her new role at Cleveland Clinic London. She also leads several international clinical studies focused on advancing cancer care.
“Dr. Shaw brings the clinical expertise, leadership experience, and strategic vision needed to build a world-class oncology program,” said Alex A. Adjei, MD, PhD, Chief, Cleveland Clinic Cancer Institute. “The new cancer center will build on Cleveland Clinic's multidisciplinary model of care, bringing together specialists in medical oncology, surgical oncology, hematology, radiology, pathology, genetics, and supportive care to create personalized treatment plans for every patient.”
The center will offer immunotherapy, chemotherapy, targeted therapies, and radiotherapy through coordinated teams focused on achieving the best outcomes for patients. Patients will also benefit from Cleveland Clinic's global cancer network of more than 800 physicians, researchers, nurses, and technicians, providing access to clinical trials, precision medicine, molecular profiling, and emerging therapies.
“Dr. Shaw’s appointment represents an important investment in the future of cancer care at Cleveland Clinic London,” said Beri Ridgeway, MD, President, Cleveland Clinic London. “Her experience developing innovative cancer services, leading multidisciplinary teams, and advancing research will be instrumental as we build a comprehensive oncology program, and expand access to exceptional cancer care for patients across the UK.”
Dr. Shaw’s clinical and research interests include melanoma and other skin cancers; rare cancers including ocular melanoma; immunotherapy; and the development of novel cancer treatments. She is a chief investigator and national coordinating investigator for multiple international studies involving cellular, immunotherapy, and vaccine-based therapies, including the recent international phase III study of an individualized mRNA cancer therapy in the adjuvant treatment of melanoma, which met its primary endpoint.
“This is an extraordinary opportunity to build a comprehensive oncology service that brings together outstanding specialists, leading-edge treatments, innovative research, and compassionate multidisciplinary patient care,” said Dr. Shaw. “By recruiting exceptional people and expanding access to emerging treatments, we have an opportunity to create a truly integrated cancer program that delivers exceptional outcomes and experience for patients and their families.”
